- Home
- EWCZ vs YMAB Comparison
EWCZ vs YMAB Comparison
Compare EWCZ & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- YMAB
- Stock Information
- Founded
- EWCZ 2004
- YMAB 2015
- Country
- EWCZ United States
- YMAB United States
- Employees
- EWCZ N/A
- YMAB N/A
- Industry
- EWCZ Package Goods/Cosmetics
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- YMAB Health Care
- Exchange
- EWCZ Nasdaq
- YMAB Nasdaq
- Market Cap
- EWCZ 300.3M
- YMAB 270.5M
- IPO Year
- EWCZ 2021
- YMAB 2018
- Fundamental
- Price
- EWCZ $6.39
- YMAB $5.54
- Analyst Decision
- EWCZ Buy
- YMAB Strong Buy
- Analyst Count
- EWCZ 7
- YMAB 10
- Target Price
- EWCZ $6.64
- YMAB $21.10
- AVG Volume (30 Days)
- EWCZ 360.7K
- YMAB 507.9K
- Earning Date
- EWCZ 03-05-2025
- YMAB 03-04-2025
- Dividend Yield
- EWCZ N/A
- YMAB N/A
- EPS Growth
- EWCZ 62.57
- YMAB N/A
- EPS
- EWCZ 0.23
- YMAB N/A
- Revenue
- EWCZ $223,500,000.00
- YMAB $84,553,000.00
- Revenue This Year
- EWCZ $1.26
- YMAB $6.41
- Revenue Next Year
- EWCZ $2.40
- YMAB $18.15
- P/E Ratio
- EWCZ $28.26
- YMAB N/A
- Revenue Growth
- EWCZ 2.42
- YMAB N/A
- 52 Week Low
- EWCZ $4.80
- YMAB $5.47
- 52 Week High
- EWCZ $15.50
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- EWCZ 41.42
- YMAB 34.53
- Support Level
- EWCZ $6.74
- YMAB $5.47
- Resistance Level
- EWCZ $7.60
- YMAB $5.78
- Average True Range (ATR)
- EWCZ 0.33
- YMAB 0.37
- MACD
- EWCZ -0.10
- YMAB 0.04
- Stochastic Oscillator
- EWCZ 5.30
- YMAB 13.56
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.